Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension

Patients with connective tissue disease-associated pulmonary arterial hypertension (PAH-CTD) have a poor prognosis compared with other aetiologies. The underlying CTD can influence treatment response and outcomes. We characterised the GRIPHON study PAH-CTD subgroup and evaluated response to selexipa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaine, Sean, Chin, Kelly, Coghlan, Gerry, Channick, Richard, Di Scala, Lilla, Galiè, Nazzareno, Ghofrani, Hossein-Ardeschir, Lang, Irene M., McLaughlin, Vallerie, Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Hoeper, Marius M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593379/
https://www.ncbi.nlm.nih.gov/pubmed/28818881
http://dx.doi.org/10.1183/13993003.02493-2016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593379/
https://www.ncbi.nlm.nih.gov/pubmed/28818881
http://dx.doi.org/10.1183/13993003.02493-2016

Ejemplares similares